Kelsey-Seybold Clinic Fort Bend Lab

CLIA Laboratory Citation Details

2
Total Citations
14
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 45D2219814
Address 11555 University Blvd, Sugar Land, TX, 77478
City Sugar Land
State TX
Zip Code77478
Phone(713) 442-9100

Citation History (2 surveys)

Survey - December 5, 2024

Survey Type: Standard

Survey Event ID: OWBX11

Deficiency Tags: D0000 D2007 D5417 D5807 D6066 D0000 D2007 D5417 D5807 D6066

Summary:

Summary Statement of Deficiencies D0000 An onsite recertification survey conducted December 5, 23, 2024 found the laboratory in compliance with 42 CFR Part 493, Requirements for Laboratories. D2007 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The samples must be examined or tested with the laboratory's regular patient workload by personnel who routinely perform the testing in the laboratory, using the laboratory's routine methods This STANDARD is not met as evidenced by: Based on review of laboratory policy, proficiency testing records from 2023 and 2024, and interview with laboratory personnel, the laboratory failed to ensure six of six consecutive routine chemistry proficiency testing events were analyzed by personnel who routinely perform chemistry testing in the laboratory. The findings included: 1. Based on review of the laboratory's policy "Proficiency Testing" (Version 3.0, LQ- 006.1), on page 3 of 14, the policy stated the following: "2.4.4 All testing personnel must participate in handling and testing of PT samples. If multiple personnel perform patient testing for the same analyte, testing of proficiency samples should be rotated among all testing personnel." 2. Based on review of American Proficiency Institute (API) proficiency testing records from 2023 and 2024, Testing Person 3 (as listed on the CMS-209 Laboratory Personnel report) attested to the analyzing six of six proficiency testing challenges for routine chemistry. 2023 - Chemistry Core - 1st event Testing Person 3 analyzed CH01-05 2023 - Chemistry Core - 2nd event Testing Person 3 analyzed CH06-10 2023 - Chemistry Core - 3rd event Testing Person 3 analyzed CH11-15 2024 - Chemistry Core - 1st event Testing Person 3 analyzed CH01-05 2024 - Chemistry Core - 2nd event Testing Person 3 analyzed CH06-10 2024 - Chemistry Core - 3rd event Testing Person 3 analyzed CH11-15 3. In an interview at 11:30 am on 12/05/2024 in the board room, the Compliance Manager confirmed the findings. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on surveyor observations and interview with laboratory personnel, the laboratory failed to ensure five of five pre-chilled grey top sodium fluoride blood collection tubes were not available for use beyond the expiration date. The findings included: 1. During a tour of the laboratory at 09:40 am on 12/05/2024, the surveyor observed five of five pre-chilled grey top sodium fluoride blood collection tubes in the refrigerator across from the chemistry instrument that had exceeded their expiration date. Lot: 3194791 Expiration date: 2024-11-30 Elapsed time: Expired by five days. 2. In an interview at 09:40 am on 12/05/2024 in the laboratory, the General Supervisor 2 (as listed on the CMS-209 Laboratory Personnel report) confirmed the blood collection tubes had exceeded the expiration date. D5807 TEST REPORT CFR(s): 493.1291(d) Pertinent "reference intervals" or "normal" values, as determined by the laboratory performing the tests, must be available to the authorized person who ordered the tests and, if applicable, the individual responsible for using the test results. This STANDARD is not met as evidenced by: Based on a review of laboratory policy, review of patient final reports, and confirmed in an interview of laboratory personnel, the laboratory failed to ensure normal reference intervals were available to health care providers for six of six relative test count results included on male and female Complete Blood Count (CBC) tests. The findings included: 1. A review of the laboratory's policy titled, "Sysmex XN-430 (SN 11473) Verification Summary under, "Reference Range" stated, "Table 6.4: Sysmex XN-430 (SN11473) Female Reference Interval Verification" and "Table 6.5: Sysmex XN-430 (SN11473) Male Reference Interval Verification". The tables did not include a patient normal range for: - % Neutrophils - % Lymphocytes - % Monocytes - % Eosinophils - % Basophils 2. A review of one female patient's final report and one male patient's final report found that the laboratory included the automated CBC relative counts on patient final reports available to healthcare providers. Specimen ID: 24FD-340H00002 (male) Final Report Date: 12/05/2024 Component Value Reference Range Neutrophils 88 Not estab. % Lymphs 7 Not estab. % Monocytes 3 Not estab. % Eos 0.0 Not estab. % Basos 0.0 Not estab. % Specimen ID: 24FD-340H00003 (female) Final Report Date: 12/05/2024 Component Value Reference Range Neutrophils 56 Not estab. % Lymphs 39 Not estab. % Monocytes 4 Not estab. % Eos 0.7 Not estab. % Basos 0.3 Not estab. % The final reports did not include a patient normal range for: - % Neutrophils - % Lymphocytes - % Monocytes - % Eosinophils - % Basophils 3. In an interview at 4:30 p.m. with the Compliance Manager and Director (as listed on the Entrance/Exit Conference Sheet) in the board room confirmed the findings. D6066 TESTING PERSONNEL QUALIFICATIONS -- 2 of 3 -- CFR(s): 493.1423(b)(4)(ii) Have documentation of training appropriate for the testing performed prior to analyzing patient specimens. This STANDARD is not met as evidenced by: Based on direct observation, a review of personnel records, and confirmed in an interview with laboratory personnel, one of three testing personnel reviewed did not have documentation of training on the Vitros 3400 chemistry analyzer used for patient testing. The findings included: 1. A tour of the laboratory on December 5, 2024, at 9: 15 hours, found the laboratory used one Vitros 3400 chemistry analyzer for patient testing. 2. A review of personnel records for testing personnel 4 (as listed on Form CMS-209) found no documentation of training for the Vitros 3400. The testing person's hire date was documented as 07/10/2023. Further review of the personnel records for testing personnel #4 found a training record from a satellite location for a different analyzer (Vitros 5600) signed off on 09/06/2023 by the testing person and the trainer. 3. In an interview at 11:10 a.m. with the Compliance Manager (as listed on the Entrance/Exit Conference Sheet) in the board room confirmed the findings. She confirmed the laboratory used a Vitros 3400, but the training records were for a Vitros 5600. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 12, 2023

Survey Type: Standard

Survey Event ID: RZ6C11

Deficiency Tags: D0000 D5461 D0000 D5461

Summary:

Summary Statement of Deficiencies D0000 Noted deficiencies and plans of correction were discussed with the laboratory representative(s) at the exit conference. The facility was found to be in compliance with applicable Conditions in the CLIA program, and recertification is recommended. D5461 CONTROL PROCEDURES CFR(s): 493.1256(d)(6)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- Perform control material testing as specified in this paragraph before resuming patient testing when a complete change of reagents is introduced; major preventive maintenance is performed; or any critical part that may influence test performance is replaced. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on the review of the manufacturer's instructions, the laboratory's reagent replace logs from 2/7/2023 to 4/7/2023, patient records, and confirmed in an interview, the laboratory failed to document a quality control run after a change in a reagent for 3 of 10 days reviewed on one of one Sysmex XN-430 hematology instrument. The findings were: 1. Review of the manufacturer's instructions titled Sysmex Automated Hematology Analyzer XN-530/XN-430/XN-330 General Information (North American Edition) (Code No. BV237179 en-am. Date of Last Revision: 08/2019. Software Version: Ver. 3 onwards.) in Chapter 7. Reagents revealed four reagents were used in the XN-430 Hematology analyzer (SN: 11473). Cellpack DCL Fluorocell WDF Lysercell WDF Sulfolyser 2. Random review of the reagent replace logs from 2/7/2023 to 4/7/2023 revealed 3 of 10 days reviewed had no documentation of a quality control run after the following reagent change on the Sysmex XN-430 hematology analyzer. 2/8/2023 at 2:14pm Fluorocell WDF Lot#: A2004 Exp: 05/19/2023 2/17/2023 at 12:16pm Lysercell WDF Lot#: A2008 Exp: 06 /14/2023 3/2/2023 at 9:44am Sulfolyser Lot#: Y2005 Exp:06/15/2023 3. Review of Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- the laboratory's QC logs for the above dates revealed the next QC was performed on the following date and time after reagent changes: Reagent change 2/8/2023 at 2: 14pm Fluorocell WDF Next QC 2/9/2023 at 7:54am Reagent change 2/17/2023 at 12: 16pm Lysercell WDF Next QC 2/17/2023 at 4:12pm Reagent change 3/2/2023 at 9: 44am Sulfolyser Next QC 3/3/2023 at 7:51am 4. Random review of the patient records for the above dates revealed the laboratory performed 40 patient CBC testing after the reagent change with no documentation of a quality control run after a change in a reagent. 2/8/2023 at 2:55pm Sample NO:1000417016 2/8/2023 at 2:59pm Sample NO:1000416995 2/8/2023 at 3:12pm Sample NO:1000417341 2/8/2023 at 3:24pm Sample NO:1000417458 2/8/2023 at 4:03pm Sample NO:1000418109 2/8/2023 at 4: 09pm Sample NO:1000417868 2/8/2023 at 4:12pm Sample NO:1000417835 2/8/2023 at 4:21pm Sample NO:1000418504 2/8/2023 at 4:24pm Sample NO:1000418500 2/8 /2023 at 5:51pm Sample NO:1000419730 2/17/2023 at 12:40pm Sample NO: 1000485730 2/17/2023 at 1:07pm Sample NO:1000487901 2/17/2023 at 2:52pm Sample NO:1000488372 2/17/2023 at 2:59pm Sample NO:1000488270 2/17/2023 at 3:33pm Sample NO:1000488539 2/17/2023 at 3:53pm Sample NO:1000489005 2/17 /2023 at 4:00pm Sample NO:1000489117 2/17/2023 at 4:04pm Sample NO: 1000489606 2/17/2023 at 4:06pm Sample NO:1000490201 2/17/2023 at 4:10pm Sample NO:1000490677 3/2/2023 at 10:03am Sample NO:1000581026 3/2/2023 at 10:07am Sample NO:1000581658 3/2/2023 at 10:21am Sample NO:1000581793 3/2 /2023 at 10:23am Sample NO:1000581942 3/2/2023 at 10:30am Sample NO: 1000581620 3/2/2023 at 10:37am Sample NO:1000581172 3/2/2023 at 10:52am Sample NO:1000581114 3/2/2023 at 11:01am Sample NO:1000582899 3/2/2023 at 11:10am Sample NO:1000583116 3/2/2023 at 11:21am Sample NO:1000583603 3/2 /2023 at 11:26am Sample NO:1000584031 3/2/2023 at 11:43am Sample NO: 1000583526 3/2/2023 at 11:57am Sample NO:1000583615 3/2/2023 at 12:29pm Sample NO:1000584488 3/2/2023 at 12:40pm Sample NO:1000585503 3/2/2023 at 1: 14pm Sample NO:1000585785 3/2/2023 at 1:16pm Sample NO:1000585496 3/2/2023 at 2:46pm Sample NO: 1000588171 3/2/2023 at 3:00pm Sample NO: 1000588589 3/2 /2023 at 3:24pm Sample NO: 1000589266 5. An interview with the clinical compliance manager on 4/12/2023 at 11:30 am in the conference room confirmed the laboratory did not perform at least a level of quality control run after a change in a reagent. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access